Related Experiment Videos
Automatic sequence design of major histocompatibility complex class I binding peptides impairing CD8+ T cell
Koji Ogata1, Alfonso Jaramillo, William Cohen
1Service de Conformation de Macromolécules Biologiques et Bioinformatique, CP263, Centre de Biologie Structurale et Bioinformatique, Université Libre de Bruxelles, Blvd. du Triomphe, Belgium.
The Journal of Biological Chemistry
|November 2, 2002
Summary
An automatic protein design method identified novel peptides that bind to the HLA-A2 major histocompatibility complex (MHC) molecule. These designed peptides show promise for T-cell therapies by binding strongly and inhibiting T-cell receptor recognition.
Area of Science:
- Computational biology
- Immunology
- Structural biology
Background:
- The Human Leukocyte Antigen (HLA) class I allele, HLA-A2, plays a crucial role in immune response by presenting peptides to T cells.
- Designing peptides that bind specifically to HLA-A2 is essential for developing targeted immunotherapies.
Purpose of the Study:
- To computationally design and experimentally validate peptide sequences with high binding affinity for the HLA-A2 molecule.
- To assess the functional impact of these designed peptides on T-cell recognition.
Main Methods:
- Utilized an automatic protein design procedure employing structural templates, a rotamer library, and an empirical force field.
- Calculated peptide sequences for six HLA-A2 structural templates, ranking them by binding energy.
- Synthesized and tested 10 designed peptides for binding affinity and stability with HLA-A2.
- Evaluated the inhibition of T-cell receptor recognition by CD8(+) T effectors for the strongest binders.
Main Results:
- All 10 computationally designed peptides successfully bound to the HLA-A2 molecule.
- Six peptides demonstrated stable HLA-A2-peptide complex formation with varying affinities.
- Three peptides significantly inhibited T-cell receptor recognition by CD8(+) T effectors.
Conclusions:
- The automatic protein design procedure is effective in generating high-affinity HLA-A2 binding peptides.
- Designed peptides can form stable complexes and modulate T-cell responses, indicating therapeutic potential.
- Structural insights into HLA-A2-peptide and T-cell receptor interactions guided the design and interpretation of results.